Zydus Cadila receives tentative FDA approval for Levofloxacin tablets

By Elaine Rigoli

Tampa, Fla., April 24 - Cadila Healthcare Ltd. has received tentative approval from the Food and Drug Administration to market Levofloxacin tablets, 250 mg, 500 mg and 750 mg.

Levofloxacin tablets, used to treat respiratory infections, had U.S. branded sales in 2005 estimated at $295 million, according to a news release.

The company will market the drug through its U.S. subsidiary, Zydus Pharmaceuticals (USA) Inc., following patent expiry, the release said.

Zydus Cadila is a pharmaceutical products company based in Mumbai, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.